Crossmark

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Crossref DOI link: https://doi.org/10.1007/s00125-015-3845-8

Published Online: 2015-12-24

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Muscelli, Elza

Astiarraga, Brenno

Barsotti, Elisabetta

Mari, Andrea

Schliess, Freimut

Nosek, Leszek

Heise, Tim

Broedl, Uli C.

Woerle, Hans-Juergen

Ferrannini, Ele
Funding

Funding for this research was provided by:

Eli Lilly and Company

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2015-12-24